Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials

• Main Authors: Kristian Reich (Author), Diamant Thaçi (Author), Georg Stingl (Author), Jens Strodl Andersen (Author), Line Conradsen Hiort (Author), Michala Oron Lexner (Author), David Winkler (Author), Carle Paul (Author)
• Format: Book
• Published: Medical Journals Sweden, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposu...